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COMMENTARY
MEDICINE AND LAW
Ethical Allocation of Preexposure
HIV Prophylaxis
Lawrence O. Gostin, JD
Susan C. Kim, JD, MPH
CIVIL SOCIETY–LEDMOVEMENTS TRANSFORMEDGLOBALAIDS action from deep skepticism about extend-ing antiretroviral (ARV) treatment in low- andmiddle-income countries to a historic scaling up
of treatment toward universal access. During its first phase
(2003-2008), the US President’s Emergency Plan for AIDS
Relief (PEPFAR)—the largest national commitment to com-
bat a single disease—supported treatment for more than 2
million people, care for more than 10 million people, and
prevention of mother-to-child transmission in 16 million
pregnancies.1 The Global Fund to Fight AIDS, Tuberculo-
sis and Malaria (Global Fund), a unique international fi-
nancing institution, has committed $19.3 billion in 144 coun-
tries to support large-scale prevention, treatment, and care,
with most resources devoted to AIDS treatment.2
The AIDS movement, however, is at an inflection point
due to the interplay of key health and economic determi-
nants—the global financial downturn, tight foreign aid bud-
gets, and intense resource competition. Even with historic
global engagement, human immunodeficiency virus (HIV)
treatment is insufficient in resource-poor settings. Al-
though 5.2 million individuals currently receive treatment
for HIV infection, 10 million more are in immediate need
and 64% of those in need live in low- and middle-income
countries.3 PEPFAR’s fiscal-year 2011 budget proposes only
a 2% increase, which will result in future treatment enroll-
ment freezes and a growing waiting list among 14 million
treatment-eligible individuals.4 Similarly, Global Fund
pledges reached only $11.7 billion for 2011-2013, failing
to meet the fund’s lowest “austerity-level” target of $13 bil-
lion—the amount needed to sustain current treatment rates.5
A report by the Institute of Medicine concluded that be-
cause treatment can only reach a fraction of those in need,
it is “not sustainable for the foreseeable future.”6
Policy makers will now have to consider implementing a
new intervention, ie, preexposure prophylaxis (PrEP). Re-
cent studies suggest that PrEP could mean a shift of ARVs
from treatment to prevention. For instance, the iPrEx
study found that menwho have sex withmen (MSM) taking
tenofovir/emtricitabinewere44% less likely tobecome infected
withHIV than those taking a placebo.7 TheCAPRISA004 trial
(a proof-of-concept study) found that vaginal tenofovir di-
soproxil fumarate gel reduced the risk of contracting HIV by
39%,8 and the CDC 4323 study (an extended safety study)
confirmed that oral tenofovir disoproxil fumarate was safe
for use as PrEP in MSM.9 Although it will take several years
to fully establish the clinical efficacy of PrEP in varying popu-
lations, these encouraging early results have accelerated global
dialogue on its proof of deliverability.
PrEP Clinical Trials
The principle underlying PrEP is that ARVs could prevent
HIV infection among individuals who are HIV negative and
at high risk. PrEP does not involve getting permission from
a partner, so it could be especially valuable for individuals
who cannot use condoms because they sell sex, are in dan-
ger of rape, or are under pressure to have sex. As of Novem-
ber 2010, therewere 8 ongoing or planned PrEP clinical trials
using tenofovir disoproxil fumarate, tenofovir disoproxil fu-
marate gel, or tenofovir/emtricitabine inAfrica, SouthAmerica,
Thailand, and the United States. The studies encompass di-
verse populations, including injecting-drug users, MSM, se-
rodiscordant heterosexual couples, and sex workers.
These studies will be completed at different times, rais-
ing the question that if a trial demonstrates effectiveness for
a given study group, should PrEP be used for others? For
example, if data prove PrEP sufficient for regulatory ap-
proval in MSM, would it be unethical to fail to offer PrEP
to HIV-negative partners in heterosexual serodiscordant
couples? In other words, are the biological pathways suffi-
ciently similar to convincingly suggest that PrEP should be
offered to at-risk populationswho could benefit without hav-
ing specific data for that risk group?
Unlike existing prevention strategies such as voluntary
counseling and testing, condoms, and male circumcision,
PrEP is a continuous biomedical intervention. Although
prevention of mother-to-child transmission also uses
ARVs, it can be accomplished in a discrete time frame—
combination therapy during themonths around delivery can
reduce perinatal transmission by more than 90%.10 Under
what circumstances is it ethical to recommend that healthy
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individuals take medications with potential adverse effects
and drug resistance? Moreover, PrEP is not likely to be a
population-wide intervention. Rather it will be a targeted
intervention within a larger combination prevention strat-
egy for at-risk populations. Given intense resource scar-
city, how can policy makers make difficult choices among
equally important interventions?
Ethical Allocation
The ethical issues raised by PrEP are difficult, but not in-
surmountable. The following guidance could help ensure
ethical allocation under circumstances of scarcity.
Comparative Cost-effectiveness. If a salient goal is to
maximize lives saved, it is essential to adopt strategies
to achieve that goal. Treatment alone clearly will not stem
the AIDS pandemic: for every 100 individuals who are pre-
sumed to be receiving treatment each year, 200 become
infected.3 Comparative cost-effectiveness research, there-
fore, should inform policy (1) regarding one prevention vs
another prevention—which interventions work best, in
what combination, and at what cost? (2) regarding preven-
tion vs treatment—would the use of ARVs for prevention
provide more benefit than treatment at less cost, or is
the cost per infection averted greater than the cost of
treatment? and (3) regarding one treatment vs another
treatment—would the use of ARVs for prevention induce
resistance to first-line treatment, requiring significantly
more expensive second- or third-line pharmaceuticals? In
assessing the costs and benefits, policy makers should take
a long-term perspective. Initial costs for PrEP could save
health systems significant resources over time. UNAIDS is
currently coordinating a larger effort to model health
outcomes and comparative cost-effectiveness to address
these questions.
Values beyond cost and benefit also may be considered.
Should priority be given to those already in treatment be-
cause it would be a hardship to discontinue their medica-
tion? Or are all treatment-eligible individuals equally de-
serving of a fair chance for treatment? Moreover, should
priority be given to themostmarginalized populations, such
as MSM, injecting-drug users, or sex workers, because they
have suffered compounding disadvantages?
Good Governance. International principles of good gov-
ernance require policy makers to act transparently, engage
relevant stakeholders, and be held accountable. Policymak-
ers must make clear the reasons for, and provide evidence
supporting, their decisions. Stakeholder engagement en-
sures that the voices of affected communities are heard. Ad-
ditionally, policymakers should be held accountable for fair
deliberation and ultimately success.
Access Barriers. Affected communities face multiple ob-
stacles in accessing services. Cost remains a key barrier, re-
quiring financial support from external sources. There also
exist numerous noncost barriers such as discrimination,
criminalization, privacy invasion, and onerous consent laws
for young individuals. Overcoming barriers requires re-
view and revision of laws to ensure that governments pro-
tect the human rights of persons living with HIV/AIDS.
Quality Improvement
If countries implement PrEP, they should continuouslymoni-
tor, evaluate, and improve services in ways that are com-
munity-specific. Risk profiles change (eg, drug resistance
and toxicity), as does the evidence base for interventions.
Ethical issues are not static but will fluctuate based on evolv-
ing research and surveillance. For example, if PrEP speeds
the evolution of drug resistance or if individuals increase
risk behavior (neither of which occurred in the iPrEx study),
policy makers would need to alter their treatment recom-
mendations.
Resource restraints will remain a pressing challenge for
the foreseeable future. The AIDS movement is at a pivotal
point in history, where it will face scrutiny not only to dem-
onstrate that interventions are cost-effective and equitably
distributed, but also to balance resource demandswith other
global health imperatives, such asmaternal/child health, non-
communicable diseases, and the human resources and in-
frastructure required to ensure the health of individuals and
communities.
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